Hem › Akut bifentypisk leukemi › Texas › Houston
Kliniska studier för Akut bifentypisk leukemi i Houston, TX
11 studier för Akut bifentypisk leukemi söker deltagare vid platser i och runt Houston (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RekryterarFas 1
- University of Texas MD Anderson Cancer Center, Houston
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RekryterarFas 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
RekryterarFas 2
- M D Anderson Cancer Center, Houston
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RekryterarFas 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekryterarFas 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekryterarFas 1/2
- University of Texas MD Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
RekryterarFas 2
- M D Anderson Cancer Center, Houston
A Study of Revumenib and Mezigdomide in People With Leukemia
RekryterarFas 1/2
- MD Anderson Cancer Center (Data Collection Only), Houston
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RekryterarFas 1/2
- M D Anderson Cancer Center, Houston
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
RekryterarFas 2
- M D Anderson Cancer Center, Houston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RekryterarFas 1
- Texas Children's Hospital/Baylor College of Medicine, Houston
Akut bifentypisk leukemi-studier i andra städer
- Seattle, WA15 studier
- New York City, NY10 studier
- Atlanta, GA9 studier
- Durham, NC8 studier
- Memphis, TN7 studier
- Chicago, IL7 studier
- Charlotte, NC6 studier
- Aurora, CO6 studier
- Baldwin Park, CA6 studier
- Portland, OR6 studier
- Los Angeles, CA6 studier
- Philadelphia, PA6 studier
Andra studier i Houston
- Icke-småcellig lungcancer145 studier
- Bröstcancer126 studier
- Cancer (alla typer)121 studier
- Metastaserande cancer104 studier
- Kolorektal cancer102 studier
- Äggstockscancer89 studier
- Akut myeloid leukemi85 studier
- Lungcancer78 studier
- Prostatacancer76 studier
- Endometriecancer68 studier
- Bukspottkörtelcancer61 studier
- Melanom59 studier
Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.